- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in glenmark pharma
Marching Towards Carbon Efficiency
Glenmark is looking to become carbon neutral by 2030 in Scope 1 and Scope 2 emissions by actively transitioning towards renewable sources of energy
Read More
Q3 Results: Glenmark's PAT Dips By 1.2% QoQ, Revenue At Rs 540 Cr
Glenmark Pharmaceuticals recorded a net profit of Rs 105 crores in quarter three of the financial year 2023(Q3FY23) against Rs 103.7 crores recorded in the corresponding quarter in the previous year, a 1.2 per cent jump year on year while the PAT dropped by 1.2 per cent quarter on quarter
Read More
Glenmark Pharma To Submit Corrective & Preventive Action Plan To USFDA
The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe, said the company
Read More
Glenmark Reports 7.2% Rise In Revenue In Q2FY23, Net Profit At Rs 278.7 Cr
Glenmark’s consolidated revenue was at Rs 3,375.2 crores as against Rs. 3,147.4 crores recording an increase of 7.2 per cent quarter on quarter
Read More
Glenmark Pharma Gets Final Approval For Birth Control Capsules
The approval granted by the US Food & Drug Administration (USFDA) to Glenmark Pharmaceuticals Inc is for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules
Read More
Coronavirus Drug Favipiravir Safe And Effective: Glenmark Pharma
The study analyzed a total of 1,803 in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate coronavirus patients.
Read More
Glenmark Pharma Q1 Net Up 21 % At Rs 306 Cr
The Mumbai-based drug major had reported a PAT of Rs 254 crore in the April-June quarter of the 2020-21 fiscal.
Read More
Glenmark Inks Deal With Sanotize For COVID Treatment Spray In India, Other Asian Mkts
SaNOtize developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections in 2017.
Read More
Glenmark Life Sciences Mobilises Rs 454 Cr From Anchor Investors Ahead Of IPO
The initial public offer (IPO) will have fresh issue of equity shares worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma.
Read More
Glenmark Pharma Gets USFDA Nod For Inhalation Product
Glenmark Pharma said the Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company's North American manufacturing facility based in Monroe, North Carolina, and marks the company's first nebulizer approval.
Read More
Glenmark Pharma Launches Anti-Epileptic Drug In US
Banzel tablets are used in combination with other medications to treat children with Lennox-Gastaut syndrome, a severe form of childhood epilepsy that also causes developmental and behavior problems.
Read More
Glenmark Arm, Emcure, 3 Other Pharma Cos Line Up Rs 7,000-Cr Ipos
The domestic pharma sector accounts for over 50 per cent of global vaccine supplies, 40 per cent of generic drug supplies to the US, and 25 per cent of all medicines to Britain.
Read More
Glenmark Pharma Launches Nasal Spray Ryaltris In India
Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.
Read More
Glenmark Arm Gets Russian Health Ministry Nod For Nasal Spray Ryaltris
Csaba Kantor Senior Vice President – Russia and CIS region, Glenmark Pharmaceuticals, said Russia is one of the key markets for the company and it consistently looking to expand its product portfolio.
Read More
Glenmark Q3 Net Profit Up 30% At Rs 248.17 Cr
Sales from the formulation business in India for the third quarter of FY 2020-21 was at Rs 882.11 crore as against Rs 788.83 crore in the previous corresponding quarter
Read More